文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

[嗅神经母细胞瘤的放射治疗]

[Radiotherapy of esthesioneuroblastoma].

作者信息

Strnad V, Grabenbauer G G, Dunst J, Sauer R

机构信息

Strahlentherapeutische Klinik und Poliklinik, Universität Erlangen-Nürnberg.

出版信息

Strahlenther Onkol. 1994 Feb;170(2):79-84.


DOI:
PMID:8108785
Abstract

AIM: To evaluate the radiocurability of esthesioneuroblastoma, we have retrospectively analyzed the results of radiation therapy in this tumor in our clinic. PATIENTS AND METHODS: From 1985 through 1990, twelve patients with esthesioneuroblastoma have been treated at the Department of Radiotherapy at the University of Erlangen. Two had Kadish stage A, one stage B, and nine stage C. There were seven males and five females with a mean age of 43 years. Eleven patients had combined transcranial-transbasal surgery prior to radiotherapy (five R0-, four R1-, and two patients R2-resections) and one received radiotherapy only. The dose was 12 to 60 Gy (mean 54 Gy) in 1.8 Gy to 2 Gy per fraction. RESULTS: 8/12 patients (67%) were locally controlled. One had progressive disease during radiotherapy after partial resection and died. Three had local recurrences, one in-field and two marginal. One patient with a local recurrence developed cervical lymph node metastases, and one locally controlled patient developed bone metastases but is alive eight years after chemotherapy plus radiotherapy for metastatic disease. The five-year-overall and recurrence-free survival was 72% and 55%, respectively. CONCLUSIONS: Sophisticated surgery plus radiotherapy may cure a reasonable number of patients with esthesioneuroblastoma.

摘要

目的:为评估嗅神经母细胞瘤的放射可治愈性,我们回顾性分析了我院该肿瘤的放射治疗结果。 患者与方法:1985年至1990年期间,埃尔朗根大学放射治疗科共治疗了12例嗅神经母细胞瘤患者。其中2例为卡迪什A期,1例为B期,9例为C期。男性7例,女性5例,平均年龄43岁。11例患者在放疗前接受了经颅 - 经基底联合手术(5例R0切除、4例R1切除、2例R2切除),1例仅接受了放疗。剂量为12至60 Gy(平均54 Gy),每次分割剂量为1.8 Gy至2 Gy。 结果:12例患者中有8例(67%)获得局部控制。1例在部分切除后放疗期间病情进展并死亡。3例出现局部复发,1例为野内复发,2例为边缘复发。1例局部复发患者发生颈部淋巴结转移,1例局部控制患者发生骨转移,但在针对转移病灶进行化疗加放疗后存活了8年。5年总生存率和无复发生存率分别为72%和55%。 结论:精细的手术加放疗可能治愈相当数量 的嗅神经母细胞瘤患者。

相似文献

[1]
[Radiotherapy of esthesioneuroblastoma].

Strahlenther Onkol. 1994-2

[2]
[Prognostic factors and outcome of esthesioneuroblastoma].

Zhonghua Zhong Liu Za Zhi. 2005-9

[3]
Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment?

Strahlenther Onkol. 2005-6

[4]
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Int J Radiat Oncol Biol Phys. 2006-3-15

[5]
Esthesioneuroblastoma: 25-year experience at a single institution.

Otolaryngol Head Neck Surg. 2008-4

[6]
Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma.

Strahlenther Onkol. 2003-4

[7]
[Long-term experiences in the therapy of esthesioneuroblastoma].

Laryngorhinootologie. 2006-10

[8]
Esthesioneuroblastoma treated with non-craniofacial resection surgery followed by combined chemotherapy and radiotherapy: An alternative approach in limited resources.

Jpn J Clin Oncol. 2006-10

[9]
Olfactory neural tumours--the role of external beam radiotherapy.

J Laryngol Otol. 1996-11

[10]
Esthesioneuroblastoma: continued follow-up of a single institution's experience.

Arch Otolaryngol Head Neck Surg. 2006-2

引用本文的文献

[1]
[Hyposmia and epistaxis. Esthesioneuroblastoma (olfactory neuroblastoma)].

Radiologe. 2004-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索